Dexcom chair Sayer sells 26,756 shares in plan

Dexcom Inc Executive Chair Kevin R. Sayer sold 26,756 shares of common stock on July 20, 2026 at a weighted average price of $76.3193 per share, in multiple trades between $75.80 and $76.62.

Rhea-AI Filing Summary

Dexcom Inc Executive Chair Kevin R. Sayer sold 26,756 shares of common stock on July 20, 2026 at a weighted average price of $76.3193 per share, in multiple trades between $75.80 and $76.62. The sale was made under a Rule 10b5-1 trading plan adopted on February 18, 2026 for orderly dispositions of his holdings. Following this sale, he directly holds 328,970 shares, including 106,972 unvested restricted stock units that were granted in 2024–2026 and will vest through 2028.

Insider Trade Summary 10b5-1

Net Seller: 26,756 shares

Net Sell 1 txn

Insider SAYER KEVIN R

Role Executive Chair

Sold 26,756 shs ($2.04M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	26,756	$76.3193	$2.04M

Holdings After Transaction: Common Stock — 328,970 shares (Direct)

Footnotes (3)

1. F1. On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
2. F2. This transaction was executed in multiple trades at prices ranging from $75.80 to $76.62. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
3. F3. Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Key Figures

Shares sold: 26,756 shares Weighted average sale price: $76.3193 per share Post-transaction holdings: 328,970 shares +5 more

8 metrics

Shares sold 26,756 shares Common stock sold by Kevin R. Sayer on July 20, 2026

Weighted average sale price $76.3193 per share Common stock sale on July 20, 2026

Post-transaction holdings 328,970 shares Direct holdings after July 20, 2026 sale

Unvested RSUs 106,972 units Included within total post-transaction holdings

RSUs grant 2026 32,749 units Granted March 8, 2026; vest through March 8, 2027

RSUs grant 2025 56,993 units Granted March 8, 2025; vest through March 8, 2028

RSUs grant 2024 17,230 units Granted March 8, 2024; vest through March 8, 2027

10b5-1 plan adoption date February 18, 2026 Date Kevin R. Sayer adopted trading plan

Key Terms

10b5-1 Plan, restricted stock units, weighted average sale price

3 terms

10b5-1 Plan regulatory

"Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly"

A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.

restricted stock units financial

"Included in this number are 106,972 unvested restricted stock units, 32,749"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price above reflects the weighted average sale price. The Reporting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Dexcom (DXCM) report for Kevin R. Sayer?

Dexcom reported that Executive Chair Kevin R. Sayer sold 26,756 shares of common stock on July 20, 2026. The weighted average sale price was $76.3193 per share, executed in multiple trades between $75.80 and $76.62.

Was the recent Dexcom (DXCM) insider sale under a Rule 10b5-1 plan?

Yes. The sale was made under a Rule 10b5-1 Plan adopted by Kevin R. Sayer on February 18, 2026. The plan is described as allowing the orderly disposition of shares owned by him, and this transaction was executed pursuant to that plan.

How many Dexcom (DXCM) shares does Kevin R. Sayer hold after the sale?

After the July 20, 2026 transaction, Kevin R. Sayer directly holds 328,970 Dexcom shares. This total includes 106,972 unvested restricted stock units that are scheduled to vest over future periods through March 8, 2028.

What unvested RSUs does Kevin R. Sayer have at Dexcom (DXCM)?

Kevin R. Sayer holds 106,972 unvested restricted stock units. These include 32,749 RSUs granted March 8, 2026; 56,993 RSUs granted March 8, 2025; and 17,230 RSUs granted March 8, 2024, vesting through 2027–2028.

What price range applied to Kevin R. Sayer’s Dexcom (DXCM) share sale?

The July 20, 2026 sale was executed in multiple trades at prices from $75.80 to $76.62 per share. The reported transaction price of $76.3193 represents the weighted average sale price across those trades, according to the filing footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/21/2026 - 04:58 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SAYER KEVIN R

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chair

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/20/2026		S		26,756(1)	D	$76.3193(2)	328,970(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.

2. This transaction was executed in multiple trades at prices ranging from $75.80 to $76.62. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

3. Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Kevin R. Sayer	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)